Cost-Effectiveness of Hepatitis-B Vaccine in Greece: A Country of Intermediate HBV Endemicity
| Autor: | Evi J. Hatziandreu, Stefanos Hatziyannis, Mark A. Kane, Angelos Hatzakis, Milton C. Weinstein |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Viral Hepatitis Vaccines Technology Assessment Biomedical Hepatitis B vaccine Cost effectiveness Cost-Benefit Analysis Health Personnel Population Environmental health medicine Humans Hepatitis B Vaccines education Hepatitis Vaccines Synthetic education.field_of_study Greece business.industry Health Policy Incidence (epidemiology) Risk of infection Vaccination Hepatitis B medicine.disease Occupational Diseases Costs and Cost Analysis business |
| Zdroj: | International Journal of Technology Assessment in Health Care. 7:256-262 |
| ISSN: | 1471-6348 0266-4623 |
| DOI: | 10.1017/s026646230000564x |
| Popis: | We evaluated the cost-effectiveness of (a) a vaccination program for the prevention of hepatitis B; and (b) the two commercially available vaccines (Merck Sharp and Dohme; Pasteur Institute) in Greece, a country of intermediate endemicity. We examined cases of hepatitis-B infection prevented and the expected medical costs among the high-risk groups of medical and nursing students, hospital personnel, and the general population. Employing a vaccination program reduces considerably the risk of infection, especially in the high-risk groups, while it increases the total cost. The vaccines are very comparable in terms of both health and economic outcomes. Sensitivity analysis indicated that vaccine cost, incidence of hepatitis B, and compliance were the key factors for the choice of (a) whether to undertake an extensive program to prevent hepatitis-B infection and its chronic sequelae; and (b) which vaccine to administer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|